Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.40 |
| ▸ | KDM5A | P29375 | 1/20 | 0.40 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.34 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
| ▸ | COMT | P21964 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | DAO | P14920 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16465773 | 0.85 | HPGD (0.33) | HCAR2KDM5AKDM4CPKMHTT | |
| SCHEMBL31032184 | 0.74 | CSNK2A1 (0.36) | HCAR2KDM5AKDM4CHTTNPSR1 | |
| SCHEMBL5867339 | 0.72 | KDM6B (0.51) | HCAR2KDM5AKDM4CPKMHSD17B2 | |
| SCHEMBL11629097 | 0.72 | MAPK1 (0.47) | HCAR2KDM5AKDM4CPKMALDH1A1 | |
| SCHEMBL11630106 | 0.71 | HSD17B2 (0.44) | HCAR2KDM5AKDM4CPKMKMT2A | |
| SCHEMBL14616426 | 0.70 | — | — | |
| SCHEMBL7513080 | 0.70 | — | — | |
| SCHEMBL1946300 | 0.68 | — | — | |
| SCHEMBL11256496 | 0.67 | HTT (0.37) | HCAR2KDM5AKDM4CHTTKMT2A | |
| SCHEMBL30754559 | 0.66 | KDM5A (0.56) | HCAR2KDM5AKDM4CPKMHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388583-A1 | COMPOUNDS AND METHOD FOR PKMYT1 INHIBITION | ENGINE BIOSCIENCES PTE LTD (SG) | 2025-12-25 | — | — | US | disclosed |
| EP-4582423-A1 | NOVEL TRICYCLIC DERIVATIVE COMPOUND AND USES THEREOF | Hanmi Pharm. Co., Ltd. (KR) | 2025-07-09 | — | — | EP | disclosed |
| CN-120077041-A | Tricyclic derivative compounds and use thereof | 韩美药品株式会社 | 2025-05-30 | — | — | CN | disclosed |
| EP-4543881-A1 | COMPOUNDS AND METHOD FOR PKMYT1 INHIBITION | Engine Biosciences Pte. Ltd. (SG) | 2025-04-30 | — | — | EP | disclosed |
| US-20240124454-A1 | TRICYCLIC COMPOUND AND USE THEREOF | NANJING ZAIMING PHARMACEUTICAL CO., LTD. (CN) | 2024-04-18 | — | — | US | disclosed |
| WO-2024080788-A1 | NOVEL TRICYCLIC DERIVATIVE COMPOUND AND USES THEREOF | 한미약품 주식회사 | 2024-04-18 | — | — | WO | disclosed |
| WO-2023249563-A1 | COMPOUNDS AND METHOD FOR PKMYT1 INHIBITION | ENGINE BIOSCIENCES PTE. LTD. (SG) | 2023-12-28 | — | — | WO | disclosed |
| EP-4273146-A1 | TRICYCLIC COMPOUND AND USE THEREOF | Nanjing Zaiming Pharmaceutical Co., Ltd. (CN) | 2023-11-08 | — | — | EP | disclosed |
| EP-4273146-A1 | TRICYCLIC COMPOUND AND USE THEREOF | Nanjing Zaiming Pharmaceutical Co., Ltd. (CN) | 2023-11-08 | — | — | EP | disclosed |
| CN-116670144-A | Tricyclic compounds and uses thereof | 南京再明医药有限公司 | 2023-08-29 | — | — | CN | disclosed |
| WO-2022143864-A1 | TRICYCLIC COMPOUND AND USE THEREOF | 江苏先声药业有限公司 | 2022-07-07 | — | — | WO | disclosed |
| WO-2022143864-A1 | TRICYCLIC COMPOUND AND USE THEREOF | 江苏先声药业有限公司 | 2022-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388583-A1 | COMPOUNDS AND METHOD FOR PKMYT1 INHIBITION | PKMYT1, PKN1, PRKCB | HCAR2 2091/4885KDM5A 3355/4885KDM4C 1400/4885 |
| US-20240124454-A1 | TRICYCLIC COMPOUND AND USE THEREOF | MAT2A, MNAT1, KAT2A | HCAR2 649/4885KDM5A 1486/4885KDM4C 1555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.